UPDATE: Tempest Therapeutics (TPST) PT Lowered to $35 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
May 13, 2022 8:00 AM EDTAnnounced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCOPresented positive preclinical data for TPST-1495 at AACRPresented positive preclinical data with proprietary small molecule TREX1 inhibitors at AACR
SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today... More
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
May 13, 2022 8:00 AM EDTAnnounced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCOPresented positive preclinical data for TPST-1495 at AACRPresented positive preclinical data with proprietary small molecule TREX1 inhibitors at AACR
SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated... More
